GRAIL, Inc.
GRAL Nasdaq· Services-Medical Laboratories
Last close · Oct 23, 2026
$132.55
KIRA · Stoqly’s AI analyst, in plain words
- GRAIL, Inc. had $147M of revenue in fiscal 2025, up 17.2% on the year before.
- Its operating margin was −382.0%, up 1,361.1 pts: of every 100 in sales, about −382 is left after running the business.
- GRAIL, Inc. lost $408M in fiscal 2025.
- Free cash flow was −$300M in fiscal 2025, −203.8% of revenue.
Market cap
$5.7B
P/E
—
Revenue
$147M
Net income
−$408M
Free cash flow
−$300M
Operating margin
−382.0%
GRAIL, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+17.2%
Yes. Sales grew 17.2% last year.
Does it make a profit?
−277.5%
No. It lost money last year.
Does profit turn into cash?
−203.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What GRAIL, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- GRAIL, Inc.
- CIK
- 0001699031
GRAIL, Inc. · GRAL
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $55.6M | $93.1M | $126M | $147M |
| Revenue growth | — | 67.6% | 34.9% | 17.2% |
| Operating margin | −9,798.2% | −1,627.6% | −1,743.0% | −382.0% |
| Net income | −$5.4B | −$1.5B | −$2.0B | −$408M |
| Net margin | −9,719.3% | −1,574.2% | −1,613.9% | −277.5% |
| Diluted EPS | −$173.89 | −$47.21 | −$63.54 | −$11.11 |
| Cash | ||||
| Cash from operations | −$561M | −$596M | −$577M | −$299M |
| Capital expenditure | $22.9M | $12.9M | $5.2M | $0.9M |
| Free cash flow | −$584M | −$609M | −$582M | −$300M |
| FCF margin | −1,051.6% | −653.8% | −463.7% | −203.8% |
| Share count change | — | 0.0% | 2.7% | 15.2% |
| Debt and strength | ||||
| Cash and short-term investments | $242M | $97.3M | $214M | $250M |
| Shareholders' equity | — | — | $2.5B | $2.6B |
| Current ratio | — | 1.0x | 10.7x | 12.0x |
| Returns and quality | ||||
| Return on equity | — | — | −81.0% | −16.1% |
| Return on tangible equity | — | — | −416.6% | −56.1% |
| Piotroski F-score | — | — | 3 | 4 |
| Altman Z'' | — | — | −8.5 | −2.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$118M
5 insiders
Of sales under plans
9%
$10.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
GRAIL, Inc. · GRAL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $132.55 a share, the company is worth $5.7B.
Source: SEC EDGAR XBRL filings (CIK 0001699031). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.